Evofem Biosciences, Inc. – NASDAQ:EVFM
Evofem Biosciences stock price today
$0.01
+0.00
+1.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Evofem Biosciences stock price monthly change
-7.41%
month
Evofem Biosciences stock price quarterly change
-7.41%
quarter
Evofem Biosciences stock price yearly change
-83.74%
year
Evofem Biosciences key metrics
Market Cap | 5.81M |
Enterprise value | 77.71M |
P/E | -0.01 |
EV/Sales | 5.60 |
EV/EBITDA | -0.65 |
Price/Sales | 0.12 |
Price/Book | -0.02 |
PEG ratio | N/A |
EPS | 9.66 |
Revenue | 16.01M |
EBITDA | -86.83M |
Income | 50.52M |
Revenue Q/Q | -37.97% |
Revenue Y/Y | -12.95% |
Profit margin | -865.51% |
Oper. margin | -790.26% |
Gross margin | 58.24% |
EBIT margin | -790.26% |
EBITDA margin | -542.33% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEvofem Biosciences stock price history
Evofem Biosciences stock forecast
Evofem Biosciences financial statements
| Jun 2023 | 2.45M | -8.55M | -348.17% |
|---|---|---|---|
| Sep 2023 | 5.11M | 66.00M | 1291.18% |
| Dec 2023 | 4.83M | -2.11M | -43.69% |
| Mar 2024 | 3.60M | -4.80M | -133.47% |
| 2025 | 193.32M | 28.29B | 14634.36% |
|---|---|---|---|
| 2026 | 241.12M | 56.58B | 23465.57% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 14074000 | 69.73M | 495.51% |
|---|---|---|---|
| Sep 2023 | 13322000 | 67.88M | 509.54% |
| Dec 2023 | 10554000 | 72.47M | 686.67% |
| Mar 2024 | 8217000 | 74.24M | 903.53% |
| Jun 2023 | -1.49M | -1K | 597K |
|---|---|---|---|
| Sep 2023 | -2.36M | 0 | 2.13M |
| Dec 2023 | -170K | 0 | 340K |
| Mar 2024 | 123K | -14K | 0 |
Evofem Biosciences alternative data
| Aug 2023 | 35 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 35 |
| Apr 2024 | 35 |
| May 2024 | 35 |
| Jun 2024 | 37 |
| Jul 2024 | 37 |
Evofem Biosciences other data
100.00%
+84.97%
of EVFM is owned by hedge funds
31
-21
7.60M
+6.29M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 10 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KAMDAR KIM P. director | Common Stock | 10 | $0.62 | $6 | ||
Purchase | PELLETIER SAUNDRA L officer: Chief Ex.. | Common Stock | 141,000 | $0.35 | $49,773 | ||
Purchase | PELLETIER SAUNDRA L director, officer.. | Common Stock | 135,000 | $0.38 | $50,625 | ||
Purchase | FILE JUSTIN J. officer: Chief Fi.. | Common Stock | 40,594 | $0.37 | $15,020 | ||
Purchase | FITZPATRICK ALEXANDER A officer: General Counsel and Se.. | Common Stock | 25,000 | $0.39 | $9,725 | ||
Purchase | KAMDAR KIM P. director, 10 percent owner | Common Stock | 10,000 | $1.17 | $11,650 | ||
Purchase | O'BRIEN ANTHONY STEPHEN director | Common Stock | 8,140 | N/A | N/A | ||
Purchase | BARRANS RUSSELL officer: Chief Commercial Officer | Common Stock | 18,180 | $1.14 | $20,725 | ||
Purchase | RARICK LISA DALE director | Common Stock | 5,000 | N/A | N/A | ||
Purchase | FITZPATRICK ALEXANDER A officer: General Counsel and Se.. | Common Stock | 10,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 9 Jan 2020 Issue date: 14 May 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2022 4 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 4 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 3 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Ms. Saundra Pelletier (1970) Pres, Chief Executive Officer & Director | $1,840,000 |
| Mr. Justin J. File (1970) Chief Financial Officer | $1,010,000 |
-
What's the price of Evofem Biosciences stock today?
One share of Evofem Biosciences stock can currently be purchased for approximately $0.01.
-
When is Evofem Biosciences's next earnings date?
Unfortunately, Evofem Biosciences's (EVFM) next earnings date is currently unknown.
-
Does Evofem Biosciences pay dividends?
No, Evofem Biosciences does not pay dividends.
-
How much money does Evofem Biosciences make?
Evofem Biosciences has a market capitalization of 5.81M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.2% to 18.22M US dollars.
-
What is Evofem Biosciences's stock symbol?
Evofem Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "EVFM".
-
What is Evofem Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Evofem Biosciences?
Shares of Evofem Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Evofem Biosciences's key executives?
Evofem Biosciences's management team includes the following people:
- Ms. Saundra Pelletier Pres, Chief Executive Officer & Director(age: 55, pay: $1,840,000)
- Mr. Justin J. File Chief Financial Officer(age: 55, pay: $1,010,000)
-
How many employees does Evofem Biosciences have?
As Jul 2024, Evofem Biosciences employs 37 workers, which is 6% more then previous quarter.
-
When Evofem Biosciences went public?
Evofem Biosciences, Inc. is publicly traded company for more then 10 years since IPO on 20 Nov 2014.
-
What is Evofem Biosciences's official website?
The official website for Evofem Biosciences is evofem.com.
-
Where are Evofem Biosciences's headquarters?
Evofem Biosciences is headquartered at 12400 High Bluff Dr Ste 600, San Diego, CALIFORNIA.
-
How can i contact Evofem Biosciences?
Evofem Biosciences's mailing address is 12400 High Bluff Dr Ste 600, San Diego, CALIFORNIA and company can be reached via phone at +1 858 550 1900.
Evofem Biosciences company profile:
Evofem Biosciences, Inc.
evofem.comExchange:
NASDAQ
Full time employees:
119
Industry:
Biotechnology
Sector:
Healthcare
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
12400 High Bluff Dr Ste 600
San Diego, CALIFORNIA 92130
San Diego, CALIFORNIA 92130
CIK: 0001618835
ISIN: US30048L1044
CUSIP: 30048L104
